VistaGen Therapeutics Inc., a clinical-stage firm that specializes in biopharmaceutical products, is currently focused on developing and commercializing a range of drugs that aim to address anxiety, depression, and central nervous system disorders. One of the company's most exciting candidates is PH94B, a neuroactive nasal spray that works rapidly to alleviate anxiety symptoms in adults with social anxiety disorder. PH94B also has potential for use with other anxiety-related disorders such as postpartum anxiety, adjustment disorder with anxiety, and panic disorders. Meanwhile, PH10 is a rapid-onset neuroactive nasal spray preparing for Phase 2B clinical trials, acting as a standalone treatment for major depressive disorder. Finally, AV-101, an oral N-methyl-D-aspartate receptor antagonist, is in development in tandem with oral probenecid as a possible treatment route for various disorders including MDD, neuropathic pain, suicidal ideation, and levodopa-induced dyskinesia. VistaGen operates with the aid of various agreements, including a contract research and development agreement with Cato Research Ltd., a license agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Based in South San Francisco, California, VistaGen Therapeutics, Inc., began operations in 1998.
VistaGen Therapeutics Inc's ticker is VTGN
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 1-10 employees working at VistaGen Therapeutics Inc
It is vistagen.com
VistaGen Therapeutics Inc is in the Healthcare sector
VistaGen Therapeutics Inc is in the Biotechnology industry
The following five companies are VistaGen Therapeutics Inc's industry peers: